Comparative Pharmacology
Head-to-head clinical analysis: EUTHROID 2 versus EUTHYROX.
Peer-Reviewed Evidence
Head-to-head clinical analysis: EUTHROID 2 versus EUTHYROX.
EUTHROID-2 vs EUTHYROX
Head-to-head clinical comparison of therapeutic indices and safety profiles.
EUTHROID-2 is a synthetic formulation of liothyronine (T3) and levothyroxine (T4) that replaces endogenous thyroid hormone. T4 is converted to the active T3 in peripheral tissues. T3 binds to thyroid hormone receptors in the cell nucleus, modulating gene transcription to increase metabolic rate, oxygen consumption, and protein, carbohydrate, and lipid metabolism.
Synthetic levothyroxine is a T4 hormone that is converted to T3, binding to thyroid hormone receptors to regulate gene transcription, increasing basal metabolic rate, cardiac output, and thermogenesis.
Hypothyroidism: replacement therapy in primary (thyroidal), secondary (pituitary), or tertiary (hypothalamic) hypothyroidismSuppression of thyrotropin (TSH) in euthyroid patients with nontoxic goiter or thyroid cancer (adjunctive therapy)
Hypothyroidism (primary, secondary, tertiary)Thyroid-stimulating hormone (TSH) suppression in thyroid cancerThyroid hormone replacement therapy in myxedema comaOff-label: Subclinical hypothyroidism (when TSH >10 mIU/L or with symptoms)
Oral, 1 tablet once daily. Each tablet contains levothyroxine 112 mcg and liothyronine 28.8 mcg.
Initial adult dose 25-50 mcg orally once daily; titrate by 12.5-25 mcg increments every 4-6 weeks; maintenance dose typically 100-200 mcg daily.
None Documented
None Documented
T4: 6-7 days (euthyroid); T3: approximately 1 day; clinical context: requires 6-8 weeks for steady state with T4 therapy.
Terminal half-life: 6-7 days in euthyroid individuals. Longer in hypothyroidism (9-10 days) and shorter in hyperthyroidism (3-4 days). Clinically, steady-state achieved in 4-6 weeks.
Levothyroxine (T4) is metabolized via deiodination by type 1 and type 2 deiodinases in peripheral tissues to the active form liothyronine (T3) and to reverse T3 (rT3). Further metabolism involves conjugation (glucuronidation and sulfation) in the liver and excretion in bile and urine.
Partially deiodinated to active T3 and inactive reverse T3 (rT3) in liver, kidney, and other tissues. Conjugation with glucuronides and sulfates. Minimal CYP450 involvement.
Renal: ~20-40% of T4 and T3 metabolites; fecal: ~40-60% as conjugated metabolites; minor biliary elimination.
Primarily renal (approximately 40-50% as unchanged drug and metabolites), with about 20% fecal elimination via bile. Minor biliary excretion.
T4: >99.95% bound to TBG, TTR, albumin; T3: ~99.7% bound to same proteins; free fraction T4 ~0.03%, T3 ~0.3%.
>99.9% bound to thyroxine-binding globulin (TBG), transthyretin (TTR), and albumin. Lewothyroxine is the active form.
T4: 0.1-0.2 L/kg (small); T3: 0.4-0.6 L/kg (larger due to less protein binding); clinical: reflects extensive tissue distribution for T3.
0.10-0.15 L/kg, reflecting distribution primarily into extracellular fluid and tissues with high affinity binding to thyroid hormone receptors.
Oral: T4 70-80% (fasting, consistent); T3 90-95%; IV: 100%.
Oral: 50-80% (variable, influenced by food, GI disease, and formulation). IV: 100%.
No dose adjustment required for mild to moderate renal impairment. For severe renal impairment (GFR < 15 mL/min), monitor thyroid function closely and consider dose reduction by 25%.
No renal adjustment required as levothyroxine is primarily metabolized and excreted in feces. Monitor TSH and free T4 in patients with severe renal impairment.
Child-Pugh A: No adjustment. Child-Pugh B: Reduce dose by 25%. Child-Pugh C: Reduce dose by 50% or avoid use.
No specific Child-Pugh adjustment; however, severe hepatic impairment may reduce T4 to T3 conversion; monitor thyroid function tests.
Weight-based dosing (levothyroxine equivalent): 1-2 mcg/kg/day orally. For neonates (0-3 months): 10-15 mcg/kg/day. Adjust based on TSH and free T4 levels.
Weight-based: 0-3 months: 10-15 mcg/kg/day; 3-6 months: 8-10 mcg/kg/day; 6-12 months: 6-8 mcg/kg/day; 1-5 years: 5-6 mcg/kg/day; 6-12 years: 4-5 mcg/kg/day; >12 years: 2-3 mcg/kg/day. Administer orally once daily.
Start with lower dose (levothyroxine equivalent 25-50 mcg/day) and titrate slowly. Monitor for cardiac effects due to increased sensitivity.
Elderly patients (especially >65 years) or those with cardiovascular disease: start at 12.5-25 mcg orally once daily; increase by 12.5 mcg every 4-6 weeks; lower maintenance doses often required.
No FDA boxed warning. However, inappropriate use (e.g., for obesity or weight loss) in euthyroid patients is dangerous and can cause serious or life-threatening toxicity, especially when combined with sympathomimetic amines.
Not approved for weight loss. Doses above physiologic requirements may produce serious or life-threatening toxicity, especially when used with sympathomimetic amines.
["Cardiac toxicity: Risk of tachyarrhythmias, angina, myocardial ischemia in patients with cardiovascular disease; start with low doses and titrate slowly","Thyrotoxic crisis: Accidental overdose may cause thyrotoxicosis or thyroid storm; monitor for symptoms of hyperthyroidism (tachycardia, chest pain, nervousness, insomnia)","Adrenal insufficiency: Thyroid hormone therapy may increase cortisol clearance and precipitate acute adrenal crisis in patients with adrenal insufficiency; treat adrenal insufficiency prior to thyroid replacement","Osteoporosis: Long-term excessive thyroid hormone may cause decreased bone mineral density","Diabetes: May alter glucose metabolism; monitor blood glucose in diabetic patients","Warfarin interaction: Thyroid hormone potentiates anticoagulant effect of warfarin; reduce warfarin dose upon initiation of thyroid therapy"]
Cardiovascular effects (angina, arrhythmias, hypertension) in patients with underlying heart disease. Risk of thyrotoxic crisis if dose is excessive. Adrenal insufficiency: adjust corticosteroid dose before starting in patients with adrenal insufficiency. Diabetes mellitus: may increase blood glucose and require adjustment of antidiabetic therapy. Osteoporosis: chronic TSH suppression increases risk of bone loss. Interactions with anticoagulants (warfarin), antidiabetic agents, and SSRIs. Discontinue use for weight loss due to serious toxicity.
["Hypersensitivity to any component of the product","Untreated or inadequately treated adrenal insufficiency","Untreated thyrotoxicosis (hyperthyroidism)","Recent myocardial infarction (relative contraindication due to risk of cardiac ischemia)","Concurrent use of sympathomimetic amines (e.g., for weight loss) may increase cardiac risk"]
Untreated adrenal insufficiency, untreated thyrotoxicosis, acute myocardial infarction, hypersensitivity to any component.
Data Pending Review
Data Pending Review
Avoid high-fiber foods, soy products, walnuts, grapefruit juice, and high-calcium foods (milk, yogurt) at the time of dosing as they can impair absorption. Take medication at least 30 minutes before meals. Foods containing goitrogens (e.g., cruciferous vegetables like broccoli, cabbage, kale) in large amounts may interfere with thyroid function but are generally not a concern with adequate iodine intake.
Levothyroxine absorption is decreased by high-fiber foods (e.g., bran, whole grains), soy products, grapefruit juice, walnuts, and cottonseed meal. Also, calcium-fortified foods and beverages can reduce absorption. Take levothyroxine at least 4 hours apart from these foods. Avoid concomitant ingestion with coffee or milk; if needed, maintain consistency. Caffeine may slightly reduce absorption.
EUTHROID-2 (levothyroxine 100 mcg + liothyronine 20 mcg) is a combination thyroid hormone replacement. Hypothyroidism itself increases risk of miscarriage and fetal neurodevelopmental deficits if untreated. Levothyroxine and liothyronine do not cross the placenta in significant amounts at physiological doses and are not associated with congenital malformations. No teratogenic effects in first trimester. In second and third trimesters, maternal euthyroidism is critical; undertreatment may lead to fetal goiter, impaired neurological development, or preterm birth. Overtreatment carries risk of maternal tachycardia, arrhythmia, and potential fetal thyrotoxicosis. The benefit of treating maternal hypothyroidism outweighs risks.
EUTHYROX (levothyroxine) is a thyroid hormone replacement. Maternal hypothyroidism itself carries significant risks to the fetus, including neurodevelopmental deficits, preterm birth, and low birth weight. The drug does not cross the placenta significantly; fetal thyroid function is independent. No known teratogenic effects from levothyroxine at therapeutic doses. First trimester: essential for maternal euthyroidism to prevent fetal neurodevelopmental impairment. Second and third trimesters: maintenance of maternal euthyroidism supports normal fetal growth and development. Insufficient treatment increases risks.
Minimal excretion into breast milk. Both levothyroxine and liothyronine are endogenous hormones; exogenous doses result in negligible transfer. Milk-to-plasma ratio (M/P) < 0.01 for levothyroxine; liothyronine M/P ~0.3. Not expected to cause adverse effects in breastfed infants at usual maternal doses. No contraindication to breastfeeding with appropriate thyroid monitoring.
Levothyroxine is excreted into breast milk in small amounts. The milk-to-plasma (M/P) ratio is approximately 0.5. It is generally considered compatible with breastfeeding at therapeutic doses as it does not pose a risk to the infant. Monitoring infant thyroid function is not routinely required unless maternal dose is very high or infant shows symptoms.
Pregnancy increases thyroid hormone requirements: increased thyroxine-binding globulin, increased plasma volume, and enhanced placental deiodinase activity. Typical dose increase of 25-50% from prepregnancy dose; some may require up to 50% more. Start increase as soon as pregnancy confirmed, guided by TSH. Split doses may be considered for liothyronine component due to short half-life. Postpartum, reduce to prepregnancy dose within 4-6 weeks.
Pregnancy increases thyroid-binding globulin and plasma volume, leading to increased levothyroxine requirements. Dose often increases by 30-50% during pregnancy, starting as early as 4-6 weeks gestation. Frequent monitoring (every 4 weeks) and dose adjustments are necessary to maintain TSH in trimester-specific ranges: first trimester 0.1-2.5 mIU/L, second trimester 0.2-3.0 mIU/L, third trimester 0.3-3.0 mIU/L. Postpartum dose should be reduced to pre-pregnancy levels.
Category C
Category C
Euthroid-2 is a synthetic combination of levothyroxine (T4) and liothyronine (T3) used for thyroid hormone replacement. Monitor TSH levels 6-8 weeks after dose changes; target TSH within normal range. T3 component may cause more rapid symptom relief but also risk of iatrogenic thyrotoxicosis if overdosed. Use with caution in elderly, cardiac disease, or adrenal insufficiency. Avoid abrupt discontinuation. Starting dose typically 50-100 mcg T4 equivalent; adjust per TSH. T3 half-life ~1 day vs T4 ~7 days; twice-daily dosing may be considered for T3 but Euthroid-2 is usually dosed once daily. Drug interactions: warfarin (increased INR), antidiabetic agents (need dose adjustment), beta-blockers (reduce T4 to T3 conversion).
Levothyroxine (EUTHYROX) is the standard therapy for hypothyroidism. Absorption is reduced by calcium, iron, soy, and fiber; take on an empty stomach 30-60 minutes before breakfast. Dose adjustments needed in pregnancy, weight changes, and with interacting drugs (e.g., estrogens, rifampin, phenytoin). Monitor TSH 6-8 weeks after dose change. In hyperthyroidism, rapid levothyroxine withdrawal can precipitate thyroid storm; taper cautiously. For myxedema coma, use IV levothyroxine (not oral). When switching from a T3-containing preparation, cross-titration is required.
Take Euthroid-2 on an empty stomach, at least 30 minutes before breakfast or 2 hours after a meal, with a full glass of water.Do not discontinue medication abruptly; consult your doctor before stopping.Report symptoms of hyperthyroidism (rapid heartbeat, anxiety, tremors, weight loss, heat intolerance) or hypothyroidism (fatigue, weight gain, cold intolerance, depression).Avoid iron supplements, calcium supplements, antacids, and sucralfate within 4 hours of taking Euthroid-2.Consistent timing and brand are important; do not switch to generic or different brand without doctor approval.Pregnancy: inform your doctor if pregnant or planning; dose may need adjustment.Regular blood tests (TSH) are required to monitor therapy.
Take levothyroxine exactly as prescribed, at the same time each day.Take on an empty stomach, at least 30-60 minutes before breakfast or any food.Do not take with calcium supplements, iron supplements, antacids, or high-fiber foods; separate by at least 4 hours.Do not stop or change dose without consulting your doctor.If you miss a dose, take it as soon as you remember, but skip if it is almost time for the next dose; do not double dose.Report symptoms of hyperthyroidism (rapid heart rate, palpitations, anxiety, weight loss) or hypothyroidism (fatigue, weight gain, cold intolerance).Blood tests (TSH) will be done regularly to monitor dose.Tell your doctor if you are pregnant, planning pregnancy, or breastfeeding.Keep all medications out of reach of children.